The impact of COVID-19 on cognition in severe cases highlights the need for comprehensive neuropsychological evaluations in all survivors
Neuropsychopharmacology
.
2021 Dec;46(13):2225.
doi: 10.1038/s41386-021-00995-7.
Epub 2021 Mar 22.
Authors
Katherine E Burdick
1
2
,
Caitlin E Millett
3
4
Affiliations
1
Mood and Psychosis Research Program, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.
[email protected]
.
2
Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
[email protected]
.
3
Mood and Psychosis Research Program, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.
4
Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
PMID:
33753883
PMCID:
PMC7983959
DOI:
10.1038/s41386-021-00995-7
No abstract available
Publication types
Comment
MeSH terms
COVID-19*
Cognition
Humans
Neuropsychological Tests
SARS-CoV-2
Survivors